

COPY OF PAPERS ORIGINALLY FILED



TECH CENTER 1600/2900

Dkt. 60772-PCT-US/JPW/GJG/CSN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rina Aharoni et al. Examiner: A. DeCloux

U.S. Serial No.: 09/768,872 Group Art Unit: 1644

Filed: January 23, 2001

FOR : TREATMENT OF AUTOIMMUNE CONDITIONS WITH

COPOLYMER 1 RELATED COPOLYMERS AND PEPTIDES

1185 Avenue of the Americas New York, New York 10036

August 23, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.97(b)(3)

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following publications which are listed again on the attached Form PTO-1449 (Exhibit A) and copies of Reference Items 1-2 (Exhibits 1-2).

This Second Supplemental Information Disclosure Statement is being submitted before the issuance of a first Office Action on the merits in connection with the subject application. Accordingly, no fee is required and this Second Supplemental Information Disclosure Statement shall be considered pursuant to 37 C.F.R. §1.97(b)(3).

- U.S. Patent No. 5,583,031, issued December 10, 1996
 (Stern) (Exhibit 1); and
- 2. Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the $\mathrm{NH_2}\text{-}\mathrm{Terminal}$ Including Proline as a Stop Signal for Trimming", $\underline{\mathrm{J.}}$

Applicants: Rina Aharoni et al.

Serial No.: 09/768,872

Filed : January 23, 2001

Page 2

Immunol., 1993, 151: 4732-4742 (Exhibit 2).

Applicants request that the Examiner review the publications and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Second Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby give to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner or Patents Washington, D.C. 20231

ohn P. White

23/02 Date

. No. 28,678

A. White John Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400